
TRSBF
Healthcare · Biotechnology · $4.26B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 30, 2021 | Time not confirmed | 0.00 | 0.03 | — |
| Mar 30, 2021 | After the close | 0.00 | 0.03 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | 0.00 | — |
| Aug 17, 2020 | Before the open | 0.00 | 0.00 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | 0.02 | — |
| Mar 30, 2020 | Before the open | 0.00 | 0.02 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | 0.02 | — |
| Aug 21, 2019 | Before the open | 0.00 | 0.02 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | 0.01 | — |
| Mar 20, 2019 | Before the open | 0.00 | 0.01 | — |
| Dec 31, 2018 | Time not confirmed | 0.00 | 0.02 | — |
| Aug 20, 2018 | Before the open | 0.22 | 0.02 | -90.4% |
| Jun 30, 2018 | Time not confirmed | 0.00 | 0.01 | — |
| Mar 26, 2018 |
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also…
| Before the open |
| 0.00 |
| 0.02 |
| — |